The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
National Taiwan University ranks 26th in Asia in latest QS rankings
11/07/2024 03:19 PM - Politics
Taiwan key to 'making America great again': Foreign minister
11/07/2024 02:41 PM - Business
Taiwan shares close up 0.82%
11/07/2024 01:47 PM - Cross-Strait
Taiwan does not oppose Lithuania restoring ties with China: FM
11/07/2024 12:01 PM - Society
3 dead, 2 injured in Kaohsiung fire
11/07/2024 11:21 AM